Abstract
Elimination of solid tumors refractory to the standard approaches is a significant challenge. The hypothesis that cancer stem cells (CSC) are responsible for the resistance to treatment, require novel therapies for cancer. Although recent studies determined phenotypes associated with CSC in distinct tumors, therapeutics lags behind. It is possible that the originally described CSC contain cells in different stages of differentiation and in different phases of the cell cycle. Most CSC should be sensitive to current treatment with enzyme inhibitors (PI3K, HDAC, PARP). In some patients, tumors recur after long periods (20-24 months) of disease free life. Novel molecular therapies, with inhibitory RNA or metastasespreventive vaccine are needed for patients which develop metastases originating from small numbers of cancer cells undetectable at the time of cure. We hypothesize that a common denominator of molecular therapies against CSC is the need for two agents: one, (available) which inhibits cell-cycle progression and a second, (to be developed) which kills “resting“ CSC.
Current Cancer Therapy Reviews
Title: Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Volume: 5 Issue: 3
Author(s): Takashi Mine, Soldano Ferrone, Georges Vlastos, George E. Peoples and Constantin G. Ioannides
Affiliation:
Abstract: Elimination of solid tumors refractory to the standard approaches is a significant challenge. The hypothesis that cancer stem cells (CSC) are responsible for the resistance to treatment, require novel therapies for cancer. Although recent studies determined phenotypes associated with CSC in distinct tumors, therapeutics lags behind. It is possible that the originally described CSC contain cells in different stages of differentiation and in different phases of the cell cycle. Most CSC should be sensitive to current treatment with enzyme inhibitors (PI3K, HDAC, PARP). In some patients, tumors recur after long periods (20-24 months) of disease free life. Novel molecular therapies, with inhibitory RNA or metastasespreventive vaccine are needed for patients which develop metastases originating from small numbers of cancer cells undetectable at the time of cure. We hypothesize that a common denominator of molecular therapies against CSC is the need for two agents: one, (available) which inhibits cell-cycle progression and a second, (to be developed) which kills “resting“ CSC.
Export Options
About this article
Cite this article as:
Mine Takashi, Ferrone Soldano, Vlastos Georges, Peoples E. George and Ioannides G. Constantin, Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA, Current Cancer Therapy Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339409788982250
DOI https://dx.doi.org/10.2174/157339409788982250 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Current Radiopharmaceuticals To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry The Arrestin Fold: Variations on a Theme
Current Genomics Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Exploration of Chemical Space Based on 4-Anilinoquinazoline
Current Medicinal Chemistry Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Glutathione Transferases: Emerging Multidisciplinary Tools in Red and Green Biotechnology
Recent Patents on Biotechnology Polyethyleneimine-Based Nanocarriers for Gene Delivery
Current Pharmaceutical Design Nano-Carriers of Combination Tumor Physical Stimuli-Responsive Therapies
Current Drug Delivery Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology In vivo Fluorescence Detection in Surgery: A Review of Principles, Methods, and Clinical Applications
Current Medical Imaging